Quantinno Capital Management LP Cuts Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

Quantinno Capital Management LP lessened its position in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 85.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 9,406 shares of the company's stock after selling 56,562 shares during the period. Quantinno Capital Management LP's holdings in Moderna were worth $629,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in MRNA. Intrinsic Value Partners LLC raised its holdings in shares of Moderna by 91.1% during the third quarter. Intrinsic Value Partners LLC now owns 51,392 shares of the company's stock valued at $3,435,000 after purchasing an additional 24,505 shares during the last quarter. Banco Santander S.A. purchased a new position in shares of Moderna during the third quarter valued at approximately $3,550,000. John G Ullman & Associates Inc. raised its holdings in shares of Moderna by 341.3% during the third quarter. John G Ullman & Associates Inc. now owns 49,650 shares of the company's stock valued at $3,318,000 after purchasing an additional 38,400 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. raised its holdings in shares of Moderna by 11.6% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,614,313 shares of the company's stock valued at $107,885,000 after purchasing an additional 167,596 shares during the last quarter. Finally, Vontobel Holding Ltd. raised its holdings in shares of Moderna by 148.2% during the third quarter. Vontobel Holding Ltd. now owns 116,088 shares of the company's stock valued at $7,758,000 after purchasing an additional 69,313 shares during the last quarter. Institutional investors own 75.33% of the company's stock.

Insider Buying and Selling

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of the stock in a transaction on Friday, November 29th. The shares were sold at an average price of $42.79, for a total transaction of $60,676.22. Following the completion of the transaction, the insider now owns 19,717 shares in the company, valued at $843,690.43. This trade represents a 6.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO James M. Mock sold 715 shares of the stock in a transaction on Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the transaction, the chief financial officer now owns 9,505 shares of the company's stock, valued at $571,440.60. This trade represents a 7.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 3,379 shares of company stock worth $158,195. 15.70% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of analysts have commented on MRNA shares. Wolfe Research started coverage on shares of Moderna in a report on Friday, November 15th. They set an "underperform" rating and a $40.00 target price for the company. Sanford C. Bernstein started coverage on shares of Moderna in a report on Thursday, October 17th. They set a "market perform" rating and a $55.00 target price for the company. UBS Group reduced their target price on shares of Moderna from $140.00 to $108.00 and set a "buy" rating for the company in a report on Thursday, October 24th. Piper Sandler reaffirmed an "overweight" rating and set a $69.00 target price (down from $115.00) on shares of Moderna in a report on Monday, November 18th. Finally, Barclays reduced their target price on shares of Moderna from $125.00 to $111.00 and set an "overweight" rating for the company in a report on Friday, November 8th. Four analysts have rated the stock with a sell rating, eleven have assigned a hold rating, five have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, Moderna has a consensus rating of "Hold" and a consensus target price of $79.50.

Moderna Price Performance

Shares of NASDAQ:MRNA traded down $0.99 during midday trading on Friday, reaching $41.83. 4,862,132 shares of the company were exchanged, compared to its average volume of 4,977,354. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. The business's fifty day moving average is $48.26 and its two-hundred day moving average is $83.22. Moderna, Inc. has a one year low of $35.80 and a one year high of $170.47. The stock has a market cap of $16.10 billion, a PE ratio of -7.19 and a beta of 1.58.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, topping analysts' consensus estimates of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The firm had revenue of $1.90 billion during the quarter, compared to analyst estimates of $1.25 billion. During the same quarter in the prior year, the business earned ($1.39) earnings per share. Moderna's revenue for the quarter was up 3.8% on a year-over-year basis. As a group, analysts predict that Moderna, Inc. will post -9.3 earnings per share for the current year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.